Cargando…

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma

Activating KRAS mutations occur in about 30% of pulmonary adenocarcinoma (AC) cases and the discovery of specific inhibitors of G12C-mutated KRAS has considerably improved the prognosis for a subgroup of about 14% of non-small cell lung cancer (NSCLC) patients. However, even in patients with a KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuchan, Elakad, Omar, Yao, Sha, von Hammerstein-Equord, Alexander, Hinterthaner, Marc, Danner, Bernhard C., Ferrai, Carmelo, Ströbel, Philipp, Küffer, Stefan, Bohnenberger, Hanibal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324032/ https://www.ncbi.nlm.nih.gov/pubmed/35888776 http://dx.doi.org/10.3390/metabo12070652

Ejemplares similares

Role of Annexin A1 in Squamous Cell Lung Cancer Progression
por: Elakad, Omar, et al.
Publicado: (2021)

One carbon metabolism in human lung cancer
por: Yao, Sha, et al.
Publicado: (2021)

Expression and prognostic impact of CD49b in human lung cancer
por: Tirilomi, Anna, et al.
Publicado: (2022)

Expression and prognostic impact of DNA-PK in human lung cancer
por: Tirilomi, Anna, et al.
Publicado: (2023)

Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer
por: Elakad, Omar, et al.
Publicado: (2022)

Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer
por: Elakad, Omar, et al.
Publicado: (2020)

Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis
por: Bremer, Sebastian C. B., et al.
Publicado: (2022)

Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer
por: Buentzel, Judith, et al.
Publicado: (2019)

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas
por: Küffer, Stefan, et al.
Publicado: (2022)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas
por: Müller, Denise, et al.
Publicado: (2021)

Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry
por: Richter, Annika, et al.
Publicado: (2021)

Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus
por: Bohnenberger, Hanibal, et al.
Publicado: (2021)

Surgical approaches for treatment of ureteropelvic junction obstruction – a systematic review and network meta-analysis
por: Uhlig, Annemarie, et al.
Publicado: (2019)

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
por: Wang, Yanxiao, et al.
Publicado: (2017)

MTHFD2- a new twist?
por: Tedeschi, Philip M., et al.
Publicado: (2016)

Association of Maternal Folate Intake and Offspring MTHFD1 and MTHFD2 Genes with Congenital Heart Disease
por: Liu, Hanjun, et al.
Publicado: (2023)

Targeting MTHFD2 in acute myeloid leukemia
por: Pikman, Yana, et al.
Publicado: (2016)

Conductive heating mattress leads to ECG changes that mimic pacemaker spikes
por: Bräuer, A., et al.
Publicado: (2020)

Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma
por: Mo, Juanfen, et al.
Publicado: (2022)

Triglyceride regulate ACE2 level through MTHFD1
por: Ma, Xiaohua, et al.
Publicado: (2021)

The catalytic mechanism of the mitochondrial methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2)
por: Zhao, Li Na, et al.
Publicado: (2022)

Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines
por: Bremmer, Felix, et al.
Publicado: (2019)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry
por: Fichtner, A., et al.
Publicado: (2022)

MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK‐3β/β‐catenin signalling
por: Shi, Yangfeng, et al.
Publicado: (2021)

Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets
por: Bremmer, Felix, et al.
Publicado: (2023)

Non‐metabolic function of MTHFD2 activates CDK2 in bladder cancer
por: Liu, Xi, et al.
Publicado: (2021)

The effect of MTHFD2 on the proliferation and migration of colorectal cancer cell lines
por: Wei, Yameng, et al.
Publicado: (2019)

Osteosyntheseverfahren bei Thoraxwandinstabilität
por: Spering, Christopher, et al.
Publicado: (2020)

S295: TACROLIMUS MODULATES CD4+ T-CELL PROLIFERATION AND FUNCTION VIA MTHFD2 IN IMMUNE THROMBOCYTOPENIA
por: Yang, LI-Ping, et al.
Publicado: (2023)

Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2)
por: Lee, Lung-Chun, et al.
Publicado: (2021)

MTHFD1 controls DNA methylation in Arabidopsis
por: Groth, Martin, et al.
Publicado: (2016)

Binding Modes of Xanthine‐Derived Selective Allosteric Site Inhibitors of MTHFD2
por: Jha, Vibhu, et al.
Publicado: (2023)

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
por: Bohnenberger, Hanibal, et al.
Publicado: (2015)

The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation
por: Gustafsson Sheppard, Nina, et al.
Publicado: (2015)

Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications
por: Ju, Huai-Qiang, et al.
Publicado: (2018)

Protein interaction and functional data indicate MTHFD2 involvement in RNA processing and translation
por: Koufaris, Costas, et al.
Publicado: (2018)

Down‐regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle‐related genes
por: Yu, Chang, et al.
Publicado: (2019)

Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy
por: Cheung, Chantal Hoi Yin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kb9cvn1k28d2tui26cgbh9uhkj